Skip to Content

Invesco Biotechnology & Genome ETF PBE

Medalist Rating as of | See Invesco Investment Hub

Morningstar’s Analysis PBE

Will PBE outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Invesco Biotechnology& Genome ETF earns a Morningstar Medalist Rating of Negative with strength in areas such as People offset by weaker spots such as Process.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the least expensive fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PBE

  • Current Portfolio Date
  • Equity Holdings 31
  • Bond Holdings 0
  • Other Holdings 3
  • % Assets in Top 10 Holdings 47.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector
5.39
12,575,906
Healthcare
5.10
11,898,097
Healthcare
5.03
11,746,651
Healthcare
5.02
11,713,531
Healthcare
4.94
11,526,709
Healthcare
4.82
11,247,151
Healthcare
4.80
11,212,122
Healthcare
4.69
10,957,835
Healthcare
4.67
10,900,737
Healthcare
2.99
6,967,970
Healthcare